[
  {
    "ts": null,
    "headline": "Take the Zacks Approach to Beat the Markets: WisdomTree, SkyWest & PepsiCo in Focus",
    "summary": "Zacks highlights gains for WisdomTree, SkyWest, and PepsiCo as its stock strategies deliver strong returns amid market volatility.",
    "url": "https://finnhub.io/api/news?id=3ed18b6a289edc19dc1d552d15fb095d93c96a6e71b6acae983fea90fbb4dbf2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756131600,
      "headline": "Take the Zacks Approach to Beat the Markets: WisdomTree, SkyWest & PepsiCo in Focus",
      "id": 136509119,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Zacks highlights gains for WisdomTree, SkyWest, and PepsiCo as its stock strategies deliver strong returns amid market volatility.",
      "url": "https://finnhub.io/api/news?id=3ed18b6a289edc19dc1d552d15fb095d93c96a6e71b6acae983fea90fbb4dbf2"
    }
  },
  {
    "ts": null,
    "headline": "J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?",
    "summary": "Johnson & Johnson stock surges above key moving averages as strong results, raised guidance and growth prospects fuel momentum.",
    "url": "https://finnhub.io/api/news?id=7a61db6e60664597f78faef55d9548619d5ef7aea98ac78bdc59054f01ff985c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756125540,
      "headline": "J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?",
      "id": 136507915,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson stock surges above key moving averages as strong results, raised guidance and growth prospects fuel momentum.",
      "url": "https://finnhub.io/api/news?id=7a61db6e60664597f78faef55d9548619d5ef7aea98ac78bdc59054f01ff985c"
    }
  },
  {
    "ts": null,
    "headline": "5 Blue-Chip Stocks to Buy as the Dow Achieves New Milestones",
    "summary": "JPM, GS, JNJ, DIS, and MSFT are five blue-chip stocks that stand out with strong growth drivers and upgraded estimates as the Dow hits record highs.",
    "url": "https://finnhub.io/api/news?id=d9be021164336ad3ce81615d46728910670d9a2ba788bea740a869d35574ee6b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756122240,
      "headline": "5 Blue-Chip Stocks to Buy as the Dow Achieves New Milestones",
      "id": 136507886,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JPM, GS, JNJ, DIS, and MSFT are five blue-chip stocks that stand out with strong growth drivers and upgraded estimates as the Dow hits record highs.",
      "url": "https://finnhub.io/api/news?id=d9be021164336ad3ce81615d46728910670d9a2ba788bea740a869d35574ee6b"
    }
  },
  {
    "ts": null,
    "headline": "[Latest] Global Targeted Drug Delivery Market Size/Share Worth USD 39.6 Billion by 2034 at a 15.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
    "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Targeted Drug Delivery Market size & share revenue was valued at approximately USD 9.8 Billion in 2024 and is expected to reach USD 11.4 Billion in 2025 and is expected to reach around USD 39.6 Billion by 2034, at a CAGR of 15.5% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Bristol-Myers Squibb, Pfiz",
    "url": "https://finnhub.io/api/news?id=ef4ddda3f0dbf2ab2312eed9c2e9350218a2f35ab69a2e7b7f5d813f53ba6026",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756121400,
      "headline": "[Latest] Global Targeted Drug Delivery Market Size/Share Worth USD 39.6 Billion by 2034 at a 15.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
      "id": 136507917,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Targeted Drug Delivery Market size & share revenue was valued at approximately USD 9.8 Billion in 2024 and is expected to reach USD 11.4 Billion in 2025 and is expected to reach around USD 39.6 Billion by 2034, at a CAGR of 15.5% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Bristol-Myers Squibb, Pfiz",
      "url": "https://finnhub.io/api/news?id=ef4ddda3f0dbf2ab2312eed9c2e9350218a2f35ab69a2e7b7f5d813f53ba6026"
    }
  },
  {
    "ts": null,
    "headline": "How Recent Pharma Tariff Delays Could Impact J&J’s Share Price in 2025",
    "summary": "If you are standing at a crossroads with Johnson & Johnson's stock, you are not alone. The past several months have given investors plenty to think about, especially as J&J continues to find its footing amid policy headlines and global market shifts. The stock recently closed at $179.29, reflecting a 12.5% gain over the past year and a steady climb of 33.8% in five years. Those are numbers that catch attention, but the real question is what they say about the future value for new and existing...",
    "url": "https://finnhub.io/api/news?id=f0ce60dc389c99916c3a6aaedf9acab5a4ddc51e97e05eeceb9cec5e945b4ca4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756116841,
      "headline": "How Recent Pharma Tariff Delays Could Impact J&J’s Share Price in 2025",
      "id": 136507918,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "If you are standing at a crossroads with Johnson & Johnson's stock, you are not alone. The past several months have given investors plenty to think about, especially as J&J continues to find its footing amid policy headlines and global market shifts. The stock recently closed at $179.29, reflecting a 12.5% gain over the past year and a steady climb of 33.8% in five years. Those are numbers that catch attention, but the real question is what they say about the future value for new and existing...",
      "url": "https://finnhub.io/api/news?id=f0ce60dc389c99916c3a6aaedf9acab5a4ddc51e97e05eeceb9cec5e945b4ca4"
    }
  },
  {
    "ts": null,
    "headline": "Got $500? 3 Dividend Stocks to Buy and Hold Forever",
    "summary": "If you're looking for income stocks, this trio of healthcare stocks is a great place to start with $500 (or $5,000).",
    "url": "https://finnhub.io/api/news?id=98b6e9690c6040583d3d955623c28b4890cf8580269665e7caf45d4d5b17bcc5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756109040,
      "headline": "Got $500? 3 Dividend Stocks to Buy and Hold Forever",
      "id": 136507919,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "If you're looking for income stocks, this trio of healthcare stocks is a great place to start with $500 (or $5,000).",
      "url": "https://finnhub.io/api/news?id=98b6e9690c6040583d3d955623c28b4890cf8580269665e7caf45d4d5b17bcc5"
    }
  },
  {
    "ts": null,
    "headline": "Harbour BioMed Appoints Yajie Li as Chief Medical Officer",
    "summary": "Harbour BioMed (the \"Company\"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced the appointment of Yajie Li as Chief Medical Officer (CMO). Ms. Li will be based in Shanghai and report directly to Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer of Harbour BioMed.",
    "url": "https://finnhub.io/api/news?id=e59b4ca631e8e6e1772f34c92c47b578300a9b4a39781df7faf17ee2a02ded8b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756083600,
      "headline": "Harbour BioMed Appoints Yajie Li as Chief Medical Officer",
      "id": 136507920,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Harbour BioMed (the \"Company\"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced the appointment of Yajie Li as Chief Medical Officer (CMO). Ms. Li will be based in Shanghai and report directly to Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer of Harbour BioMed.",
      "url": "https://finnhub.io/api/news?id=e59b4ca631e8e6e1772f34c92c47b578300a9b4a39781df7faf17ee2a02ded8b"
    }
  }
]